News|Videos|April 8, 2026
Q1 2026 Recap: Hepatology News and Updates
Author(s)Abigail Brooks, MA
Fact checked by: Victoria Johnson
Q1 2026 hepatology highlights include advances in MASH, hepatitis B, gene editing for AATD, and the first approved therapy for pruritus in PBC.
Advertisement
Advertisement
The first quarter of 2026 brought a wave of momentum in hepatology, with advances spanning metabolic liver disease, viral hepatitis, rare genetic disorders, and symptom-directed care. From regulatory designations to late-stage clinical data and US Food and Drug Administration (FDA) approvals, the landscape continues to evolve rapidly, with a growing emphasis on disease modification and precision-based approaches.
Advertisement
Advertisement